文章核心观点 - 公司与TrueNorth Medical Physics LLC达成合作协议,为放射肿瘤科部门提供第三方支持服务,以增强其部门的能力 [1][2][3][4][5] - TrueNorth团队拥有丰富的临床经验,可为公司的TomoTherapy、Radixact和CyberKnife系统提供物理、剂量学和调试支持 [2][3] - 该合作为医疗专业人员提供了另一种选择,以获得所需的资源来推进癌症治疗 [4][5] 公司概况 - 公司致力于通过创新的放射治疗技术来改善更多生命 [6] - 公司总部位于威斯康星州麦迪逊,在全球范围内拥有多个设施 [6] 行业趋势 - 放射医学领域自X射线发现125年来一直在不断发展 [2] - 当前医疗环境下,人员短缺和运营挑战可能会阻碍医院维持所需的人员水平来满足临床需求和标准 [5]

Accuray Incorporated (ARAY) recently announced that the Chinese National Medical Products Administration (NMPA) approved the registration dossier of the Accuray Precision Treatment Planning System (TPS).The CNNC-Accuray joint venture Tomo C radiation therapy system and the Accuray Precision TPS are now compatible. These are likely to provide medical teams with a new way to administer highly accurate and precise radiation treatments, as well as expand access to care for more cancer patients in China.More on ...

文章核心观点 - 公司宣布其Accuray Precision®治疗计划系统(TPS)在中国获得批准,可与CNNC-Accuray联合研发的Tomo® C放射治疗系统配合使用,为中国癌症患者提供更精准的放射治疗选择[1][2][3] - Tomo C系统采用螺旋成像和放射传递技术,可实现更精准的剂量控制,适用于多种标准和复杂的放射治疗适应症[4] - 公司表示此次批准是在中国市场的重要里程碑,有助于满足当地对精准放射治疗的未被满足需求[2] 公司概况 - 公司致力于拓展放射治疗的潜力,为复杂病例提供创新解决方案,同时也为常见病例提供更简单的治疗方案[5] - 公司总部位于美国威斯康星州麦迪逊,在全球范围内拥有多个运营设施[5] 行业概况 - 中国在2020年约占全球新发癌症病例的25%[8] - 公司表示此次批准有助于满足中国对精准放射治疗的未被满足需求[2]

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:3D Systems Corporation (DDD) is 3D printing solutions company. The Zacks Consensus Estimate for its current year earnings has been revised 11.1% downward over the last 60 days.Accuray Incorporated (ARAY) is a radiation oncology company. The Zacks Consensus Estimate for its current year earnings has been revised 128.6% downward over the last 60 days.Brenntag SE (BNTGY) is a chemical distribution company.The Zacks Consensus Estimate for ...

MADISON, Wis., May 22, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the Jefferies Global Healthcare Conference 2024. The management team is scheduled to participate in a fireside chat on Wednesday, June 5, 2024 at 7:30am EDT/4:30am PDTA live webcast of the call will also be available from the Investor Relations section of the company's website at investors.accuray.com. A webcast replay can be accessed on the website and will remain available for 90 days.About ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value per share ARAY The Nasdaq Stock Market LLC FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission F ...

Accuray Incorporated (ARAY) reported a loss per share of 6 cents for the third quarter of fiscal 2024 against the year-ago period’s earnings per share (EPS) of a penny. The metric was also wider than the Zacks Consensus Estimate of a loss of a penny per share.Revenues in DetailAccuray registered revenues of $101.1 million in the third quarter of fiscal 2024, down 14.3% year over year. The figure lagged the Zacks Consensus Estimate by 11.8%.The overall top-line growth was dampened by lower revenues from both ...

财务数据和关键指标变化 - 第三季度产品订单增长21%,调整汇率影响后增长23%,订单量对应的账单比率为1.8 [48] - 过去12个月的总订单增长8%,账单比率为1.5 [49] - 第三季度收入为1.01亿美元,同比下降14%,主要由于少发货8台设备 [51][52] - 第三季度产品收入为5000万美元,同比下降21% [52] - 第三季度服务收入为5200万美元,同比下降7% [54] - 第三季度毛利率为28.7%,上年同期为32.8%,主要受中国业务毛利递延和汇率不利影响 [56][57] 各条业务线数据和关键指标变化 - 中国业务过去12个月产品收入增长17% [53] - EIMEA地区过去12个月产品收入增长7% [53] - 日本地区第三季度收入下降11%,订单下降8%,主要受汇率不利影响 [31] - 美洲地区第三季度收入下降38%,过去12个月下降15%,订单第三季度增长7%,过去12个月下降19% [32][33] 各个市场数据和关键指标变化 - EIMEA地区第三季度收入增长5%,订单增长29%,预计全年实现双位数收入和订单增长 [28] - APAC地区过去12个月收入增长7%,订单增长14% [30] - 日本地区是公司第二大市场,第三季度60%订单来自替换竞争对手系统 [31] - 美国市场第三季度收入下降38%,过去12个月下降15%,订单第三季度增长7%,过去12个月下降19%,主要受资本支出预算缩减影响 [32][33] 公司战略和发展方向及行业竞争 - 公司长期战略目标不变,包括未来3年内实现4-6%收入复合增长和调整后EBITDA翻番 [11][45] - 公司正在进入快速增长的放射治疗市场,推出创新产品和服务,为未来几年的收入和利润增长奠定基础 [13][45] - 公司正在加强在中国和印度等新兴市场的业务拓展,提高在这些高增长市场的渗透率 [37][38] - 公司正在与法国IUCT-Oncopole和航空公司Airbus合作,开发基于人工智能的放射治疗系统性能预测解决方案,以提高服务利润率 [39] 管理层对经营环境和未来前景的评论 - 公司对长期发展前景保持信心,但第三季度业绩受到美国市场放缓和汇率不利影响的影响 [10][44] - 美国市场放缓主要由于医院资本支出预算缩减,预计在2025财年下半年和2026财年逐步恢复 [14][15][23][32] - 中国Tomo C系统获批后,公司将解除相关毛利递延,有助于未来收入和利润增长 [16][17][30] - 公司将采取更贴近客户、提供灵活融资等措施,维护在美国市场的地位,为未来市场复苏做好准备 [33][34] 问答环节重要的提问和回答 问题1 **Young Li 提问** 询问中国Tomo C系统配套治疗计划系统获批的最新进展和对2025财年的影响 [82][83] **Ali Pervaiz 回答** 预计在本财年内获得最终批准,届时将解除相关毛利递延,有助于未来收入和利润增长,具体影响公司将在下一季度财报时分享 [87][88][89] 问题2 **Brooks O'Neil 提问** 询问公司在当前不利环境下的执行情况,是否有任何需要改进的地方 [93][94] **Suzanne Winter 回答** 公司已识别一些需要改进的地方,如产品成本控制等,同时也取得了一些积极进展,如订单增长、安装基数扩大等,将继续努力提升整体经营表现 [94][95][96][97][98][99] 问题3 **Jason Wittes 提问** 询问未来指引调整的主要原因,以及中国Tomo C系统获批对收入的影响 [108][109][112][113] **Ali Pervaiz 回答** 主要由于美国市场放缓,中国Tomo C系统获批主要影响毛利递延的确认时间,不会对收入产生直接影响 [109][112][113]

Accuray (ARAY) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to earnings of $0.01 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -500%. A quarter ago, it was expected that this radiation oncology company would post a loss of $0.07 per share when it actually produced a loss of $0.10, delivering a surprise of -42.86%.Over the last four quarters, the compa ...

Exhibit 99.1 Accuray Reports Fiscal 2024 Third Quarter Financial Results MADISON, Wis, May 1, 2024 — Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the third quarter and nine-months ended March 31, 2024. Third Quarter Fiscal 2024 Summary • Net revenue of $101.1 million decreased 14 percent from the same period in the prior fiscal year. Net revenue on a constant currency basis was $102.4 million, which represented a 13 percent decrease from the same period in the prior fiscal year. ...